Mylan( ) has introduced a generic version of its EpiPens after public outrage over its pricing. But TheStreet’s Jim Cramer says he’s happy the company rolled back prices, but he still isn’t a fan of the stock.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
